Clinical trials: Gefitinib
Advanced Tumor
Phase I Study of AZD2171 co-Administered With Fixed Multiple Oral Doses of ZD1839 in Patients With Advanced Cancer
Phase I AZD2171 in combination with ZD1839 study recruiting patients with advanced cancer
- Trial name
- NCT00502060
- Testing
- AZD2171, ZD1839
- Where
- 3 sites in Netherlands
- Volunteers
- 65 people
- Sponsor
- AstraZeneca
NSCLC
Iressa v BSC (Best Supportive Care) in First Line NSCLC
The purpose of the study is to determine if the addition of Iressa to Best Supportive Care treatment will increase the progression free survival of chemo-naïve, poor performance status patients, with stage IIIB or IV NSCLC.
- Trial name
- INSTEP (NCT00259064)
- Testing
- Gefitinib
- Where
- 36 sites in Australia, Canada and 3 more
- Volunteers
- 216 people
- Sponsor
- AstraZeneca
Non-Small Cell Lung Cancer
A Phase I Study of Safety and Pharmacokinetics of Volitinib in Combination With Gefitinib in EGFR(+) NSCLC
This is a Phase 1b, open-label, multicentre study of AZD6094 in combination with gefitinib in patients with epidermal growth factor receptor (EGFR) mutation positive (m+) and progressed on EGFR Tyrosine kinase inhibitor (TKI)…
- Trial name
- NCT02374645
- Testing
- Volitinib, gefitinib
- Where
- China
- Volunteers
- 64 people
- Sponsor
- Hutchison Medipharma Limited
Non-Small Cell Lung Cancer
A Study of BGB324 (Bemcentinib) in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer
A Phase 1/2 multi-center open-label study of BGB324 (bemcentinib) as a single agent (Run-in Cohort) and in combination with erlotinib (Arms A, B, and C) in participants with Stage IIIb or Stage IV non-small cell lung cancer…
- Trial name
- NCT02424617
- Testing
- Erlotinib, Bemcentinib
- Where
- 10 sites in United States
- Volunteers
- 40 people
- Sponsor
- BerGenBio ASA
Non Small Cell Lung Cancer
A Study to Evaluate Safety and Efficacy of HS-10296 as First-Line Treatment in Patients
This is a randomized, controlled, double-blind, multicenter, phase III clinical study.
- Trial name
- NCT03849768
- Testing
- HS-10296, Gefitinib
- Where
- China
- Volunteers
- 429 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Carcinoma, Renal Cell
Study Of SU011248 Plus Gefitinib (Iressa) In Patients With Advanced Renal Cell Carcinoma
To assess the maximum tolerated dose and overall safety and tolerability of sunitinib [SU011248] administered in combination with gefitinib (Iressa) for the treatment of patients with metastatic renal cell carcinoma (Phase 1).
- Trial name
- NCT00113529
- Testing
- Gefitinib + Sunitinib
- Where
- 3 sites in United States
- Volunteers
- 42 people
- Sponsor
- Pfizer
Non-Small-Cell Lung Carcinoma
Maintenance ZD1839 (IRESSA®) Following Completion of Front Line, Platinum-Based, Double Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer
In this Phase IIIb, randomized, double-blind, maintenance study, 300 subjects with advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) (Stage IIIB {T4-pleural effusion} and IV) who have SD or objective tumor response…
- Trial name
- IMAC/Herbst (NCT00090675)
- Testing
- ZD1839
- Sponsor
- AstraZeneca
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer
Alflutinib Mesylate Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer （FLAG）
To assess the efficacy and safety of Alflutinib Mesylate versus Gefitinib in patients with locally advanced or Metastatic Non Small Cell Lung Cancer
- Trial name
- NCT03787992
- Testing
- Gefitinib 250 mg
- Where
- China
- Volunteers
- 358 people
- Sponsor
- Allist Pharmaceuticals, Inc.
EGFR Mutation Positive Non Small Cell Lung Cancer
First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Small Cell Lung Cancer Who Are Taking Standard of Care Therapy
Phase I: evaluate the safety and tolerability two different dosing regimens of Thymosin alpha 1 in patients with advanced EGFR mutation positive NSCLC on Standard of Care (SoC) therapy.
- Trial name
- NCT02906163
- Testing
- Thymalfasin (Thymosin alpha 1, Ta1), SoC (tyrosine kinase inhibitor)
- Where
- 5 sites in Italy
- Volunteers
- 188 people
- Sponsor
- SciClone Pharmaceuticals
Cancer
Liver Function Test (LFT) Elevations in Cancer Patients and Users of Tyrosine Kinase Inhibitor (TKI) Drugs
A retrospective cohort study using the LabRx medical claims database will be performed to address these objectives. The primary objective of this project is to examine the background rates of liver function test (LFT)…
- Trial name
- NCT01098500
- Testing
- Tyrosine kinase inhibitors
- Volunteers
- 3,800 people
- Sponsor
- GlaxoSmithKline
Solid Tumors, Non-small Cell Lung Carcinoma
A Study of DS-2248 in Participants With Advanced Solid Tumors
This phase 1 clinical trial is intended to understand the safety and tolerability of a new anticancer drug in subjects with advanced solid tumors.
- Trial name
- NCT01288430
- Testing
- DS-2248
- Where
- 9 sites in United States
- Volunteers
- 60 people
- Sponsor
- Daiichi Sankyo
Non Small Cell Lung Carcinoma
Concordance of Key Actionable Genomic Alterations as Assessed in Tumor Tissue and Plasma in Non Small Cell Lung Cancer
A study to determine the concordance of key actionable genomic alterations as assessed in tumor tissue and plasma from patients with non small cell lung carcinoma (NSCLC)
- Trial name
- NCT02762877
- Where
- 22 sites in United States, Chile and 5 more
- Volunteers
- 140 people
- Sponsor
- Genomic Health®, Inc.
Locally Advanced or Metastatic NSCLC
ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC
To assess the efficacy and safety of ASK120067 versus a standard of care epidermal growth factor receptor tyrosine kinase inhibitor Gefitinib in patients with locally advanced or Metastatic Non Small Cell Lung Cancer
- Trial name
- NCT04143607
- Testing
- ASK120067, Gefitinib
- Where
- 3 sites in China
- Volunteers
- 337 people
- Sponsor
- Jiangsu Aosaikang Pharmaceutical Co., Ltd.
Carcinoma, Non Small Cell Lung
A Study of Pemetrexed and Gefitinib Versus Gefitinib in Non-Small Cell Lung Cancer (NSCLC)
The purpose of this study is to compare the combination of pemetrexed and gefitinib versus gefitinib alone, in terms of progression-free survival.
- Trial name
- NCT01469000
- Testing
- Gefitinib, Pemetrexed
- Where
- 25 sites in China, Japan and 2 more
- Volunteers
- 195 people
- Sponsor
- Eli Lilly and Company
Carcinoma, Non-Small-Cell Lung
Trial of BIBW 2992 (Afatinib) + Cetuximab in Non-Small Cell Lung Cancer
The primary objective of this trial is to determine the maximum tolerated dose (MTD) and recommended Phase II doses for the combination of BIBW 2992 and cetuximab in patients with non-small cell lung cancer and acquired…
- Trial name
- NCT01090011
- Testing
- Cetuximab, BIBW 2992
- Where
- 6 sites in United States, Netherlands
- Volunteers
- 171 people
- Sponsor
- Boehringer Ingelheim
Carcinoma, Non-Small-Cell Lung, Lung Neoplasms
Study Evaluating the Safety Of HKI-272 (Neratinib) In Subjects With Advanced Non-Small Cell Lung Cancer
The purpose of this study is to learn whether HKI-272 is safe and effective in treating non-small cell lung cancer.
- Trial name
- NCT00266877
- Testing
- HKI-272
- Where
- 19 sites in United States, France and 3 more
- Volunteers
- 172 people
- Sponsor
- Puma Biotechnology, Inc.
Lung Cancer
Gefitinib Usage and Outcomes in Routine Treatment
The purpose of this study is to understand real world gefitinib usage patterns, patient characteristics and outcomes and to present these for a Caucasian population
- Trial name
- NCT01818947
- Where
- 12 sites in United Kingdom
- Volunteers
- 157 people
- Sponsor
- AstraZeneca
Cancer of Head and Neck
IRESSA in Combination With Cisplatin & Radiotherapy in Patients With Advanced Head & Neck Carcinoma
· To evaluate the disease free survival rate at 2 years of patients with advanced head and neck carcinoma treated with ZD1839 250 mg administered once daily in combination with cisplatin and a standard course of radiotherapy.
- Trial name
- NCT00242749
- Testing
- Gefitinib, Cisplatin and Radiotherapy
- Where
- 4 sites in Spain
- Volunteers
- 47 people
- Sponsor
- AstraZeneca
Prostate Cancer
Open Label Trial to Assess Iressa in Prostate Cancer Patients
A study to assess the activity of Iressa in patients who's prostate cancer has recurred, and who have rising PSA levels
- Trial name
- NCT00635856
- Testing
- Gefitinib
- Volunteers
- 100 people
- Sponsor
- AstraZeneca
Healthy
Bioequivalence Study of Gefitinib Tablets Under Fed Conditions
The study design is an Open-Label，Randomized, Single-Dose, 2-way Crossover Bioequivalence Study. During each session, the subjects will be administered a single dose of 250mg Gefitinib Tablet (one Gefitinib Tablet 250mg of Hunan…
- Trial name
- NCT03050177
- Testing
- Gefitinib Tablet 250mg of Hunan Kelun, Iressa® Tablet 250mg of AZN
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Hunan Kelun Pharmaceutical Co., Ltd.